Spravato vs SSRIs: Finding Relief When Antidepressants Fail

You've done the waiting. Four weeks on one medication, eight weeks on another, maybe a third after that. Each time, the same pattern: side effects that showed up right away, and relief that never quite followed. Now you're looking at options you hadn't considered before, and Spravato keeps coming up.

You want to know whether it works better than the SSRIs that haven't helped you, what treatment actually feels like, whether you can afford it, and whether it's the only option beyond traditional antidepressants.

You're not alone in asking. Roughly one in three people with depression don't respond adequately to standard antidepressant treatment. That's a medically recognized pattern, not a personal failure.

The bottom line: Spravato works through a different brain pathway than SSRIs and can bring relief within hours or days for some people. But it requires twice-weekly clinic visits, mandatory monitoring, and a driver for every appointment. If daily pills have let you down but clinic-based treatment feels hard to manage, at home ketamine therapy is a third option worth understanding.

What Are SSRIs and Spravato?

You already know SSRIs (selective serotonin reuptake inhibitors). Fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro): daily pills that increase serotonin availability in your brain. They're the standard first-line treatment for depression, and for many people, they work well. For you, they haven't.

Spravato is the brand name for esketamine, a prescription nasal spray the FDA approved in 2019 specifically for adults whose depression hasn't responded to at least two prior antidepressants.

Esketamine is one of two molecules in racemic ketamine, but it's delivered as a standalone nasal spray under a tightly structured clinic protocol. (For more on the molecule and clinic protocol, see how Spravato works.)

In January 2025, the FDA expanded Spravato's approval to allow it as a standalone treatment for treatment-resistant depression. Previously, you had to take it alongside an oral antidepressant. If you've been wondering whether you'd need to stay on a medication that isn't helping, the monotherapy approval matters.

Spravato also differs from compounded ketamine products offered by some telehealth services. The FDA has warned providers about compounded ketamine nasal sprays, which lack the safety monitoring built into Spravato's program.

How They Work Differently

SSRIs and Spravato target different systems in your brain. That difference explains both why SSRIs can take weeks and why Spravato may help even after SSRIs have not.

SSRIs increase serotonin availability so brain cells can communicate more effectively. Relief typically takes four to eight weeks, and sometimes longer.

Spravato appears to affect glutamate, a brain chemical involved in communication and learning. According to Johns Hopkins, it increases glutamate levels, which has a greater impact on more brain cells at once. That shift appears to support new connections between brain cells, especially in regions tied to mood. Researchers call this process neuroplasticity.

The FDA prescribing label notes that the exact mechanism behind esketamine's antidepressant effect "is unknown." In plain terms, researchers have a leading explanation, but not a final answer yet.

What the Research Shows About Effectiveness

What Happens When Antidepressants Don't Work

The NIH-funded STAR*D trial, the largest real-world study of antidepressant treatment, tracked what happens as people move through one medication after another. The pattern is stark: roughly 50% of people achieve remission within their first two medication attempts combined.

After that, each additional antidepressant trial produces a 20 to 30% drop in effectiveness. By the third or fourth try, only about 10 to 14% of people reach remission.

If those numbers land hard, that makes sense. They're not a verdict on you. They explain why so many people start looking beyond another SSRI.

What the Spravato Trials Show

Spravato's clinical trial program tested the drug specifically in people with treatment-resistant depression, the medical term for when at least two standard antidepressants haven't worked. Across pooled phase 3 data, remission rates ranged from 27% to 50%, with some people responding within the first 24 hours.

If Spravato helps you, staying on it can reduce relapse risk. In the SUSTAIN-1 trial, people who continued treatment after achieving remission had a 51% lower risk of relapse than those who stopped. Long-term data from SUSTAIN-3 followed over 1,100 people for up to 6.5 years, and only 5.3% discontinued because the medication stopped working.

A 2023 head-to-head trial in the New England Journal of Medicine (ESCAPE-TRD) compared esketamine against extended-release quetiapine, both added to an SSRI or SNRI (serotonin-norepinephrine reuptake inhibitor), in 676 people with treatment-resistant depression.

At eight weeks, 27% of the esketamine group reached remission versus 18% of the quetiapine group. Spravato outperformed a common next-line treatment, though no large trial has compared it directly against staying on an SSRI alone.

Where Spravato Falls Short

Even with that showing, Spravato has real constraints. Its meta-analytic effect sizes are small to moderate, and about 27% of people who reached stable remission relapsed even while continuing treatment. It helps many people, but it isn't a cure for everyone.

Side Effects and Tradeoffs

The side effect profiles look very different. That matters because side effects shape what life on treatment actually feels like.

Spravato's effects are acute and session-bound. Dizziness (33%), dissociation (28%), nausea (25%), and headache (25%) are the most common, based on the SUSTAIN-2 trial of 802 people. Most of these effects peak around 40 minutes after the dose and resolve within two hours. They tend to be most intense during the first two sessions and diminish from there.

SSRI side effects are chronic and ongoing. A study of people followed for one to two years found that 63% had side effects, most commonly dry mouth, sweating, sexual dysfunction, and weight gain. Sexual dysfunction is the side effect most often cited as a reason for stopping, and it persists as long as you take the medication. Spravato's sexual dysfunction rate in clinical trials is typically under 1%.

Spravato's FDA boxed warning covers sedation, dissociation, respiratory depression, abuse potential, and suicidal thoughts. SSRIs carry a boxed warning for suicidal thoughts in young people. That doesn't automatically make one option wrong for you, but it's part of the tradeoff.

What Treatment Actually Feels Like

If you take an SSRI, you know the routine. A pill each morning, maybe with food to reduce stomach upset, and then you wait. Weeks pass. You might notice changes in sleep or appetite before any shift in mood.

Spravato is a different kind of commitment. You self-administer the nasal spray at a REMS-certified clinic (Risk Evaluation and Mitigation Strategy, an FDA safety program) while a clinician watches. Then you stay for at least two hours of monitoring that includes blood oxygen checks. You can't eat for two hours before treatment or drink for 30 minutes before, and you need a driver for every visit. You can't drive or make important decisions for the rest of the day.

During the first month, you go twice a week. After that, sessions drop to once a week, then every one to two weeks during maintenance.

During a session, you may feel a floating or detached sensation, dizziness, nausea, or perceptual changes. Those short-term effects are the reason the monitoring period exists.

Cost Differences

Generic SSRIs are among the cheapest medications available, often $4 to $15 a month with a discount card and frequently covered with a small copay through insurance. No clinic visits or special prescriber credentials are needed.

Spravato is a different financial picture. Without insurance, the drug alone for the eight-session induction phase runs more than $8,000, before clinic and supervision fees. With commercial insurance, the manufacturer's savings program can bring eligible people's medication costs to as little as $10 per session.

Medicare covers Spravato as a provider-administered drug with 20% coinsurance after the deductible. If you don't have insurance, the Johnson & Johnson Patient Assistance Foundation may provide the medication at no cost for up to a year, with income thresholds starting at $45,180 for a single-person household.

The hidden costs matter too. Arranging a driver twice a week for a month, taking time from work or family obligations, and the administrative effort of prior authorization all add up in ways that dollar figures don't capture.

Comparing Your Options

Deciding What Makes Sense for You

Consider Spravato if you've tried two or more antidepressants without adequate relief, you can commit to the clinic visit schedule, you have insurance coverage or qualify for financial assistance, and speed of relief is a priority. The January 2025 monotherapy approval also means you may no longer need to continue an oral antidepressant alongside it.

Consider staying with or switching SSRIs if you haven't yet tried two full antidepressant trials at adequate doses, the convenience of daily at-home treatment matters most, or you're managing well enough that waiting four to eight weeks for a new medication feels tolerable.

Consider at-home ketamine therapy if clinic logistics are a barrier, you want therapeutic support built into your treatment, or you're looking for a middle ground between daily pills and twice-weekly clinic visits. People feeling nervous about ketamine often find the at-home format easier to approach because the environment is familiar.

You don't have to force yourself into the most medicalized option if the logistics would make treatment hard to sustain. The best option is the one you can realistically continue.

How Innerwell's At-Home Ketamine Therapy Works

Spravato isn't the only way to access ketamine-based treatment for treatment-resistant depression. At-home ketamine therapy is a different model: sublingual tablets prescribed off-label by a psychiatrist, with licensed therapeutic support built into every step. While ketamine is FDA-approved as an anesthetic, its use for depression is off-label, supported by a substantial body of clinical research.

This isn't ketamine dropped off with minimal supervision. Ketamine may open a window of neuroplasticity, a period when your brain can be more receptive to forming new patterns. The medication opens a door; therapy helps you walk through it.

The process:

1. Evaluation: A licensed clinician reviews your history, current symptoms, and treatment goals to determine whether ketamine therapy is appropriate for your situation.
2. Delivery: Your prescribed sublingual ketamine tablets are shipped directly to your home. No clinic visits, no waiting rooms, no driver to arrange for every appointment.
3. Preparation and integration: Licensed Master's and Doctoral-level mental health professionals work with you before and after each session. Preparation sets intentions. Integration is where you process what comes up and translate it into real changes.
4. Ongoing monitoring: Your clinical team tracks your progress and adjusts your treatment plan based on how you're responding.

Pricing: Treatment plans start as low as $54 per session with insurance. The Foundation plan includes 8 doses for $599 with insurance or $998 self-pay. The Extended plan includes 24 doses for $1,299 with insurance or $1,999 self-pay. Compare that to $400–$800 per session at many IV infusion clinics, or the combined drug and facility costs of Spravato.

Program outcomes: People in Innerwell's program see a 69% reduction in depression symptoms and a 60% reduction in anxiety symptoms after 10 weeks. 87% of people see improvement within four weeks, and the program holds a 4.7 out of 5 average patient rating.

Take our free assessment to see if ketamine therapy might be right for you.

Frequently Asked Questions

Do you have to take an antidepressant with Spravato?

Not always. As of January 2025, the FDA allows Spravato as monotherapy for treatment-resistant depression. You no longer have to pair it with an oral antidepressant. One exception: if you're prescribed Spravato for major depression with acute suicidal ideation, you'll still need to take an oral antidepressant alongside it.

How long do people typically stay on Spravato?

Spravato has no fixed endpoint. Some people continue for months, others stay on it for years. Ongoing reassessment matters, so it's worth checking in periodically about whether the benefit still feels worth the time, cost, and effort.

Can you stay on an SSRI while trying ketamine therapy?

Often, yes. Many people continue their current antidepressant during ketamine therapy, especially in the early phase when stopping a medication abruptly carries its own risks. A 2025 JAMA Psychiatry study of more than 55,000 people on esketamine found those paired with an SNRI had lower rates of relapse and hospitalization than those paired with an SSRI, while the SSRI group had fewer suicide attempts. The right partner medication takes clinical judgment, so coordinate the decision with your prescriber rather than improvising.